Cargando…

Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents

Prostate cancer (PCa) is a clinically heterogeneous disease with a progressively increasing incidence. Concurrent inhibition of coactivator-associated arginine methyltransferase 1 (CARM1) and histone deacetylase 2 (HDAC2) could potentially be a novel strategy against PCa. Herein, we identified seven...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Sudong, Geng, Yifei, Niu, Miao-Miao, Zhang, Yan, He, Weiping, Li, Jindong, Yang, Li, Xu, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399481/ https://www.ncbi.nlm.nih.gov/pubmed/37528657 http://dx.doi.org/10.1080/14756366.2023.2241118

Ejemplares similares

Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment
por: Zhou, Maojun, et al.
Publicado: (2021)

Discovery of potent and noncovalent KRAS(G12D) inhibitors: Structure-based virtual screening and biological evaluation
por: Wang, Yuting, et al.
Publicado: (2022)

Discovery of potent heat shock protein 90 (Hsp90) inhibitors: structure-based virtual screening, molecular dynamics simulation, and biological evaluation
por: Xu, Yonghua, et al.
Publicado: (2023)

Differential CARM1 expression in prostate and colorectal cancers
por: Kim, Young-Rang, et al.
Publicado: (2010)

Discovery of BRAF/HDAC Dual Inhibitors Suppressing Proliferation of Human Colorectal Cancer Cells
por: Li, Yingjun, et al.
Publicado: (2022)

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
por: Cincinelli, Raffaella, et al.
Publicado: (2018)

Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Design, synthesis and biological evaluation of VEGFR-2/HDAC dual inhibitors as multitargeted antitumor agents based on fruquintinib and vorinostat
por: Gao, Yali, et al.
Publicado: (2023)

Re: CaRMS at 50
por: MacFarlane, Malcolm
Publicado: (2020)

Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer
por: Guerra, Fabiana Sélos, et al.
Publicado: (2021)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: King, Jacob, et al.
Publicado: (2021)

Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors
por: Dong, Hang, et al.
Publicado: (2019)

The CARM1 transcriptome and arginine methylproteome mediate skeletal muscle integrative biology
por: vanLieshout, Tiffany L., et al.
Publicado: (2022)

Identification of novel and potent dual-targeting HDAC1/SPOP inhibitors using structure-based virtual screening, molecular dynamics simulation and evaluation of in vitro and in vivo antitumor activity
por: Yang, Yingxue, et al.
Publicado: (2023)

Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer
por: Roy, Rubi, et al.
Publicado: (2023)

Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors
por: Wang, Suhua, et al.
Publicado: (2022)

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
por: Luo, Yuxiang, et al.
Publicado: (2020)

Universidad Autónoma del Carme, Informe de actividades 2009-2010 /

Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection
por: Xu, Zhen, et al.
Publicado: (2022)

CARM1 Mediates Modulation of Sox2
por: Zhao, Hai-yong, et al.
Publicado: (2011)

Discovery of New Uracil and Thiouracil Derivatives as Potential HDAC Inhibitors
por: Elbatrawy, Omnia R., et al.
Publicado: (2023)

Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
por: Zhao, Qian, et al.
Publicado: (2022)

Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells
por: Fioravanti, Rossella, et al.
Publicado: (2020)

Natural chalcones as dual inhibitors of HDACs and NF-κB
por: ORLIKOVA, B., et al.
Publicado: (2012)

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)
por: Sinatra, Laura, et al.
Publicado: (2020)

Discovery of dual S-RBD/NRP1-targeting peptides: structure-based virtual screening, synthesis, biological evaluation, and molecular dynamics simulation studies
por: Hu, Chunfang, et al.
Publicado: (2023)

Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase 1 (HDAC1) Dual Inhibitors Derived from the Natural Product Saprorthoquinone
por: Lin, Yang, et al.
Publicado: (2020)

Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
por: Zhao, Qian, et al.
Publicado: (2023)

Pedagogía de la expresión con Carme Aymerich /
por: Farreny Terrado, María Teresa, 1957-
Publicado: (2001)

CARM1 automethylation is controlled at the level of alternative splicing
por: Wang, Lu, et al.
Publicado: (2013)

CaRMS at 50: Making the match for medical education
por: Gallinger, John, et al.
Publicado: (2020)

CARM1 Regulates AMPK Signaling in Skeletal Muscle
por: Stouth, Derek W., et al.
Publicado: (2020)

Response to letter to the editor “Re: ‘CaRMS at 50’”
por: Gallinger, John, et al.
Publicado: (2020)

The arginine methyltransferase Carm1 is necessary for heart development
por: Jamet, Sophie, et al.
Publicado: (2022)

Carm1 and the Epigenetic Control of Stem Cell Function
por: Saber, John, et al.
Publicado: (2022)

The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors
por: Zhang, Xuan, et al.
Publicado: (2013)

Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release
por: Daniel, Kevin B., et al.
Publicado: (2015)

Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer
por: Gajendran, Chandru, et al.
Publicado: (2023)

HDAC inhibitor confers radiosensitivity to prostate stem-like cells
por: Frame, F M, et al.
Publicado: (2013)

The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression
por: Grypari, Ioanna Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dpeq1ro8tj492gd1qc1fv6hagn